nach oben

Erschienen in:

21.01.2021 | Review

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

verfasst von: Dana M. Harris, Fernando F. Stancampiano, M. Caroline Burton, Ann M. Moyer, Michael J. Schuh, Jose R. Valery, Yan Bi

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.

Lima JJ, Thomas CD, Barbarino J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.2015.CrossRefPubMed

Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–534CrossRef

Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol. 2001;13:S43-47PubMed

Dean L. Esomeprazole Therapy and CYP2C19 Genotype. 2012 Oct 1 [Updated 2019 Sep 23]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda MD: National Center for Biotechnology Information (US); 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100896/.

Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24:334–344CrossRef

Adam T, Aliferis CF. Personalized and precision medicine informatics: a workflow-based view. Cham: Springer; 2020.CrossRef

Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genom. 2010;4:278–281CrossRef

Scott SA, Sangkuhl K, Shuldiner AR et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genom. 2012;22:159–165CrossRef

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526CrossRef

10.

Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95:2–8CrossRef

11.

Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008;65:437–439CrossRef

12.

Payan M, Rouini MR, Tajik N, Ghahremani MH, Tahvilian R. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population. Daru 2014;22:81CrossRef

13.

Baldwin RM, Ohlsson S, Pedersen RS et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008;65:767–774CrossRef

14.

Gumus E, Karaca O, Babaoglu MO et al. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol. 2012;68:629–636CrossRef

15.

Franciosi JP, Mougey EB, Williams A et al. Association between CYP2C19*17 alleles and pH probe testing outcomes in children with symptomatic gastroesophageal reflux. J Clin Pharmacol. 2018;58:89–96CrossRef

16.

Deshpande N, Sharanya V, Ravi Kanth V et al. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene 2016;9:159–164CrossRef

17.

Hunfeld NG, Mathot RA, Touw DJ et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008;65:752–760CrossRef

18.

El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447–460CrossRef

19.

Saito Y, Serizawa H, Kato Y et al. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol. 2015;21:13548–13554CrossRef

20.

Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: Evidence for a differential effect. Drug Metab Dispos. 2010;38:894–897CrossRef

21.

Franciosi JP, Mougey EB, Williams A et al. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. Eur J Pediatr. 2018;177:69–77CrossRef

22.

Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis. In Proceedings of the AGREE Conference. Gastroenterology. 2018 vol 155, pp. 1022–1033 e1010.

23.

Mougey EB, Williams A, Coyne AJK et al. CYP2C19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2019;69:581–587CrossRef

24.

Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics 2019;13:39CrossRef

25.

Pratt VM, Del Tredici AL, Hachad H et al. Recommendations for Clinical CYP2C19 genotyping allele selection: A report of the association for molecular pathology. J Mol Diagn. 2018;20:269–276CrossRef

26.

Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343–350CrossRef

27.

Pulley JM, Denny JC, Peterson JF et al. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92:87–95CrossRef

28.

Bielinski SJ, St Sauver JL, Olson JE et al. Cohort profile: the right drug, right dose, right time: Using genomic data to individualize treatment protocol (RIGHT protocol). Int J Epidemiol. 2020;49:23–24kCrossRef

29.

Pereira NL, Farkouh ME, So D et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 2020;324:761–771CrossRef

30.

Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019;9:40CrossRef

31.

Moyer AM, Caraballo PJ. The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoecon Outcomes Res. 2017;17:567–577CrossRef

32.

Swen JJ. Pharmacogenetics: from bench to byte--an update of guidelines www.pharmgkb.org. Published 2011. Accessed.

33.

Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016;73:1967–1976CrossRef

34.

Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800-808 e807CrossRef

35.

Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019;21:1224–1232CrossRef

Titel: Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice
verfasst von: Dana M. Harris
Fernando F. Stancampiano
M. Caroline Burton
Ann M. Moyer
Michael J. Schuh
Jose R. Valery
Yan Bi
Publikationsdatum: 21.01.2021
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 12/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-020-06814-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Liver Biopsy in Pregnancy: Two Case Reports and Review of the Literature

P63 Deficiency and CDX2 Overexpression Lead to Barrett’s-Like Metaplasia in Mouse Esophageal Epithelium

A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists

Recurrence of Clostridium Difficile and Cytomegalovirus Infections in Patients with Ulcerative Colitis Who Undergo Ileal Pouch-Anal Anastomosis

Long-Term Dietary Changes in Subjects with Glucose Galactose Malabsorption Secondary to Biallelic Mutations of SLC5A1

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin